Skip to main content
Oct 7, 2026

Dr. Protze's lab grows living cells to restore the heart’s electrical system

Research Highlights
Two women smiling, one with long brown hair and blue top, the other with shoulder-length hair.
Dr. Stephanie Protze, left, and first author Michelle Lohbihler, right.
By MoGen News

Protze Lab research develops stem cell-derived pacemaker cells that could provide a biological conduction bridge for patients with heart block

Researchers in the lab of Dr. Stephanie Protze, Assistant Professor in the Department of Molecular Genetics and Scientist at the McEwen Stem Cell Institute at UHN, have developed stem cell derived pacemaker cells that can reproduce key functions of the heart’s natural electrical relay.

The findings were published in Cell Stem Cell.

To keep the heart beating in a coordinated rhythm, there is a small group of specialized cells called the atrioventricular node, or AVN. The AVN receives the electrical signal that starts each heartbeat and briefly pauses it before passing the signal to the ventricles. This pause is crucial because it allows the upper chambers of the heart to finish contracting before the lower chambers contract.

When the pacemaker cells of the AVN do not function properly, it can lead to a life threatening condition called atrioventricular block, or AV block. AV block is currently treated with electronic pacemakers, which help restore the heart’s rhythm but have limitations. Their batteries eventually need to be replaced through additional procedures, and implanted devices can carry a risk of infection. They also cannot fully reproduce how the heart’s natural electrical system responds to changes in the body.

But what if you could grow the pacemaker cells needed for the AVN to function? That is what Protze and her team set out to investigate, whether living AV node like pacemaker cells could be generated from human stem cells and used to restore this electrical connection.

“Our goal is to replace the batteries and wires of an electronic pacemaker with a biological solution,” says Protze.

To make these cells, the researchers started with human pluripotent stem cells, which can develop into many different cell types. They then controlled Wnt and BMP signalling, two biological pathways that help guide how cells develop. By adjusting these signals at specific stages, the team was able to generate AV node like pacemaker cells, or AVNLPCs.

Generating AVNLPCs was only the first step. The researchers needed to determine whether the cells actually resembled the pacemaker cells found in the human heart. By examining patterns of gene activity, the team found that their lab grown cells closely resembled AV node pacemaker cells from developing human heart tissue.

Then came another important question. Could AVNLPCs actually do the job of the AVN?

The AVN does more than pass an electrical signal from one part of the heart to another. It also controls the timing of those signals and acts as a gatekeeper. When electrical activity in the upper chambers becomes too fast, the AVN can limit how many signals reach the ventricles, helping protect the lower chambers from beating too quickly.

The researchers tested whether AVNLPCs could reproduce these electrical properties in engineered heart tissue. The cells produced the characteristic slower electrical conduction of the natural AVN, demonstrating that they did more than resemble AV node cells. They also reproduced an important part of their function.

The team then tested the cells in a living heart. After transplanting AVNLPCs into a guinea pig model, the researchers demonstrated that the cells could support electrical conduction in vivo. This showed that the cells could reproduce important properties of the AVN not only in engineered tissue, but also within a living heart.

Together, these experiments support what Protze calls a “biological conduction bridge,” using living cells to restore electrical communication between the upper and lower chambers of the heart.

The research began in 2018 as one of the first projects in the newly established Protze Lab. First author Michelle Lohbihler joined the lab as a Molecular Genetics graduate student and continued the project through her PhD. Within about six months, the team had developed an initial method for generating the cells. The following years were spent refining the protocol and determining how best to test whether the cells worked.

The project brought together expertise from across U of T and UHN. Professor Gary Bader in Molecular Genetics contributed to the analysis used to compare the lab grown cells with their counterparts in the developing human heart. The team also worked with researchers specializing in electrophysiology and cardiac animal models to test how the cells behaved electrically.

One of the biggest challenges came when the team moved into animal studies. Their original model did not work as expected, leading the researchers to rethink their approach and develop a simpler model that allowed them to test the cells’ electrical properties.

The COVID 19 pandemic created another challenge. The lab had about a year of data when the pandemic began. Restricted laboratory access and rotating schedules slowed the research, particularly the animal studies.

The researchers are now working toward testing AVNLPCs in a pig model of AV block. This will allow them to examine how long the transplanted cells continue to function and whether they can provide reliable electrical conduction without causing abnormal heart rhythms or other adverse effects.

Protze sees particular potential for children who require pacemakers early in life. Electronic pacemakers do not grow with a child and may require repeated procedures over a lifetime. Living cells could potentially integrate with the heart and grow with the patient.

There is still considerable testing required before the approach could move into clinical studies. Protze expects that initial testing in people would likely involve older patients, with an electronic pacemaker in place while researchers evaluate the cells.

For now, the study demonstrates that AVNLPCs generated from human stem cells can reproduce important electrical functions of the natural AVN. The findings provide a foundation for further testing of whether these living cells could eventually restore electrical communication in hearts affected by AV block.

Acknowledgements

This research was supported by the Canadian Institutes of Health Research, the Canada Foundation for Innovation, the Government of Canada’s New Frontiers in Research Fund, the Canada Research Chairs Program, BlueRock Therapeutics and UHN Foundation.